2004 CJC-1295/Ipamorelin is studied as a high-selectivity alternative to CJC-1295/GHRP-6 combinations preserving GH stimulation amplitude while eliminating cortisol and prolactin co-secretion associated with GHRP-6
The biotech developing it (Cleara Biotech, from Erasmus University research) has discussed disease targets, but that is development interest, not proof
One reconstitution event reduces aseptic-technique risk, one fridge slot instead of three, and a fixed ratio for protocols where the ratio is held constant
A 6% dropout rate for a treatment producing 22.7% weight loss is remarkably low
Berenguer CV, Pereira F, Cmara JS, Pereira JAM
They act through an initial electrostatic interaction with the negatively charged compounds of the bacterial cytoplasmic membrane followed by insertion and permeabilization of the membrane